News

November 17th, 2022

HemoShear Therapeutics to Participate in Piper Sandler Healthcare Conference

Read More »
October 18th, 2022

HemoShear Therapeutics to Participate in SVB Leerink Securities Biopharma Private Company Connect

Read More »
October 11th, 2022

Shear Insights: HemoShear Therapeutics Has Built a World Class Drug Discovery Organization to Advance its Rare Disease Portfolio

Read More »
September 21st, 2022

HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics’ Gout Discovery Pipeline

Read More »
August 25th, 2022

HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer

Read More »
August 10th, 2022

HemoShear Develops New Human Tissue-Based Model of Rare Liver Disease Under Research Collaboration with Takeda

Read More »

The JUMP Study Poster

Read More »
April 14th, 2022

Shear Insights: HemoShear Therapeutics Presents Pilot Data from MMA and PA Natural History Study

Read More »

The JUMP Study

Read More »
December 14th, 2021

HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer

Read More »
November 22nd, 2021

Shear Insights: HemoShear to be Featured at International Metabolic Conference

Read More »
November 16th, 2021

HemoShear Identifies Second Target to Treat Nash for Takeda

Read More »
View More +

Contact

info@hemoshear.com

HemoShear Therapeutics, Inc.
501 Locust Avenue
Suite 301
Charlottesville, Virginia 22902